<DOC>
	<DOCNO>NCT02709382</DOCNO>
	<brief_summary>This Phase 1 , open label , single-dose , pharmacokinetic study conduct male female subject normal impaired renal function . The study compose five group patient mild ( 6 patient ) , moderate ( 6 patient ) , severe ( 6 patient ) renal impairment , end stage renal disease patient hemodialysis ( 6 patient ) respective match control 1:1 ratio ( 24 healthy subject normal renal function ) .</brief_summary>
	<brief_title>A Single-dose Study Investigate Pharmacokinetics Intravenous FEP-TAZ Patients With Renal Impairment</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Tazobactam</mesh_term>
	<mesh_term>Cefepime</mesh_term>
	<criteria>Patients renal impairment : mild , moderate , severe patient hemodialysis ) stable OR Healthy Subjects : Have normal renal function No evidence disease condition may affect pharmacokinetics FEPTAZ . Evidence hepatorenal nephritic syndrome Any clinically significant abnormal finding medical history , physical examination , clinical laboratory test ( associate control diabetes , hypertension , hypercholesterolemia , dyslipidemia , renal impairment relate causative disease )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>